Global (United States, European Union and China) Leuprolide Acetate

Leuprolide Acetate Comprehensive Study by Type (Intramuscular, Subcutaneous), Application (Prostate Cancer, Precocious, Uterine Fibroid, Others) Players and Region - Global Market Outlook to 2027

Leuprolide Acetate Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Leuprolide acetate is a synthetic nonapeptide which is a potent gonadotropin-releasing hormone receptor (GnRHR) agonist used for diverse clinical applications, containing the treatment of prostate cancer, uterine fibroids, endometriosis, central precocious puberty and in vitro fertilization techniques. By way of its basic mechanism of a deed, leuprolide acetate conquers gonadotrope secretion of luteinizing hormone and follicle-stimulating hormone which consequently suppresses gonadal sex steroid production. It is currently being tested for the treatment of Alzheimer's disease, short stature, functional bowel disease, polycystic ovary syndrome, premenstrual syndrome and even as a substitute for contraception.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)
Key Companies ProfiledTolmar Pharmaceuticals (United States), Varian Pharmed (Iran), Sigma-Aldrich (United States), Takeda Pharmaceutical (Japan), AbbVie (United States), Sanofi (France), Astellas Pharma (Japan), Abbott Laboratories (United States), Sun Pharmaceutical Industries (India) and Livzon Pharmaceutical (China)


This growth is primarily driven by Usage of Leuprolide Acetate to Treat Advanced Prostate Cancer in Men and Rising Demand Due To Early Puberty Concerns in Children.

Globally, a noticeable market trend is evident Increasing Use of Leuprolide Acetate for Uterine Fibroid. Major Players, such as Tolmar Pharmaceuticals (United States), Varian Pharmed (Iran), Sigma-Aldrich (United States), Takeda Pharmaceutical (Japan), AbbVie (United States), Sanofi (France), Astellas Pharma (Japan), Abbott Laboratories (United States), Sun Pharmaceutical Industries (India) and Livzon Pharmaceutical (China) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Market Drivers
  • Usage of Leuprolide Acetate to Treat Advanced Prostate Cancer in Men
  • Rising Demand Due To Early Puberty Concerns in Children

Market Trend
  • Increasing Use of Leuprolide Acetate for Uterine Fibroid

Restraints
  • High Cost of Product

Opportunities
Favorable Government Healthcare Guidelines

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Leuprolide Acetate Market
- Analysis about New Entrants in Leuprolide Acetate Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Leuprolide Acetate Study Sheds Light on
— The Leuprolide Acetate Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Leuprolide Acetate industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Leuprolide Acetate industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Intramuscular
  • Subcutaneous
By Application
  • Prostate Cancer
  • Precocious
  • Uterine Fibroid
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Usage of Leuprolide Acetate to Treat Advanced Prostate Cancer in Men
      • 3.2.2. Rising Demand Due To Early Puberty Concerns in Children
    • 3.3. Market Challenges
      • 3.3.1. Concerns Regarding Side Effects of Leuprolide Acetate
    • 3.4. Market Trends
      • 3.4.1. Increasing Use of Leuprolide Acetate for Uterine Fibroid
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Leuprolide Acetate, by Type, Application and Region (value, volume and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Leuprolide Acetate (Value)
      • 5.2.1. Global Leuprolide Acetate by: Type (Value)
        • 5.2.1.1. Intramuscular
        • 5.2.1.2. Subcutaneous
      • 5.2.2. Global Leuprolide Acetate by: Application (Value)
        • 5.2.2.1. Prostate Cancer
        • 5.2.2.2. Precocious
        • 5.2.2.3. Uterine Fibroid
        • 5.2.2.4. Others
      • 5.2.3. Global Leuprolide Acetate Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Leuprolide Acetate (Volume)
      • 5.3.1. Global Leuprolide Acetate by: Type (Volume)
        • 5.3.1.1. Intramuscular
        • 5.3.1.2. Subcutaneous
      • 5.3.2. Global Leuprolide Acetate by: Application (Volume)
        • 5.3.2.1. Prostate Cancer
        • 5.3.2.2. Precocious
        • 5.3.2.3. Uterine Fibroid
        • 5.3.2.4. Others
      • 5.3.3. Global Leuprolide Acetate Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Leuprolide Acetate (Price)
      • 5.4.1. Global Leuprolide Acetate by: Type (Price)
  • 6. Leuprolide Acetate: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Tolmar Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Varian Pharmed (Iran)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sigma-Aldrich (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Takeda Pharmaceutical (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. AbbVie (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Abbott Laboratories (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Livzon Pharmaceutical (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Leuprolide Acetate Sale, by Type, Application and Region (value, volume and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Leuprolide Acetate (Value)
      • 7.2.1. Global Leuprolide Acetate by: Type (Value)
        • 7.2.1.1. Intramuscular
        • 7.2.1.2. Subcutaneous
      • 7.2.2. Global Leuprolide Acetate by: Application (Value)
        • 7.2.2.1. Prostate Cancer
        • 7.2.2.2. Precocious
        • 7.2.2.3. Uterine Fibroid
        • 7.2.2.4. Others
      • 7.2.3. Global Leuprolide Acetate Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Leuprolide Acetate (Volume)
      • 7.3.1. Global Leuprolide Acetate by: Type (Volume)
        • 7.3.1.1. Intramuscular
        • 7.3.1.2. Subcutaneous
      • 7.3.2. Global Leuprolide Acetate by: Application (Volume)
        • 7.3.2.1. Prostate Cancer
        • 7.3.2.2. Precocious
        • 7.3.2.3. Uterine Fibroid
        • 7.3.2.4. Others
      • 7.3.3. Global Leuprolide Acetate Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Leuprolide Acetate (Price)
      • 7.4.1. Global Leuprolide Acetate by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Leuprolide Acetate: by Type(USD Million)
  • Table 2. Leuprolide Acetate Intramuscular , by Region USD Million (2016-2021)
  • Table 3. Leuprolide Acetate Subcutaneous , by Region USD Million (2016-2021)
  • Table 4. Leuprolide Acetate: by Application(USD Million)
  • Table 5. Leuprolide Acetate Prostate Cancer , by Region USD Million (2016-2021)
  • Table 6. Leuprolide Acetate Precocious , by Region USD Million (2016-2021)
  • Table 7. Leuprolide Acetate Uterine Fibroid , by Region USD Million (2016-2021)
  • Table 8. Leuprolide Acetate Others , by Region USD Million (2016-2021)
  • Table 9. South America Leuprolide Acetate, by Country USD Million (2016-2021)
  • Table 10. South America Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 11. South America Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 12. Brazil Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 13. Brazil Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 14. Argentina Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 15. Argentina Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 16. Rest of South America Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 17. Rest of South America Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 18. Asia Pacific Leuprolide Acetate, by Country USD Million (2016-2021)
  • Table 19. Asia Pacific Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 20. Asia Pacific Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 21. China Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 22. China Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 23. Japan Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 24. Japan Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 25. India Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 26. India Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 27. South Korea Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 28. South Korea Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 29. Taiwan Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 30. Taiwan Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 31. Australia Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 32. Australia Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 33. Rest of Asia-Pacific Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 34. Rest of Asia-Pacific Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 35. Europe Leuprolide Acetate, by Country USD Million (2016-2021)
  • Table 36. Europe Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 37. Europe Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 38. Germany Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 39. Germany Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 40. France Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 41. France Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 42. Italy Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 43. Italy Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 44. United Kingdom Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 45. United Kingdom Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 46. Netherlands Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 47. Netherlands Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 48. Rest of Europe Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 49. Rest of Europe Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 50. MEA Leuprolide Acetate, by Country USD Million (2016-2021)
  • Table 51. MEA Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 52. MEA Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 53. Middle East Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 54. Middle East Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 55. Africa Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 56. Africa Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 57. North America Leuprolide Acetate, by Country USD Million (2016-2021)
  • Table 58. North America Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 59. North America Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 60. United States Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 61. United States Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 62. Canada Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 63. Canada Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 64. Mexico Leuprolide Acetate, by Type USD Million (2016-2021)
  • Table 65. Mexico Leuprolide Acetate, by Application USD Million (2016-2021)
  • Table 66. Leuprolide Acetate Sales: by Type(Litres)
  • Table 67. Leuprolide Acetate Sales Intramuscular , by Region Litres (2016-2021)
  • Table 68. Leuprolide Acetate Sales Subcutaneous , by Region Litres (2016-2021)
  • Table 69. Leuprolide Acetate Sales: by Application(Litres)
  • Table 70. Leuprolide Acetate Sales Prostate Cancer , by Region Litres (2016-2021)
  • Table 71. Leuprolide Acetate Sales Precocious , by Region Litres (2016-2021)
  • Table 72. Leuprolide Acetate Sales Uterine Fibroid , by Region Litres (2016-2021)
  • Table 73. Leuprolide Acetate Sales Others , by Region Litres (2016-2021)
  • Table 74. South America Leuprolide Acetate Sales, by Country Litres (2016-2021)
  • Table 75. South America Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 76. South America Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 77. Brazil Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 78. Brazil Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 79. Argentina Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 80. Argentina Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 81. Rest of South America Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 82. Rest of South America Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 83. Asia Pacific Leuprolide Acetate Sales, by Country Litres (2016-2021)
  • Table 84. Asia Pacific Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 85. Asia Pacific Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 86. China Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 87. China Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 88. Japan Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 89. Japan Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 90. India Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 91. India Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 92. South Korea Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 93. South Korea Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 94. Taiwan Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 95. Taiwan Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 96. Australia Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 97. Australia Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 98. Rest of Asia-Pacific Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 99. Rest of Asia-Pacific Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 100. Europe Leuprolide Acetate Sales, by Country Litres (2016-2021)
  • Table 101. Europe Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 102. Europe Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 103. Germany Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 104. Germany Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 105. France Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 106. France Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 107. Italy Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 108. Italy Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 109. United Kingdom Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 110. United Kingdom Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 111. Netherlands Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 112. Netherlands Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 113. Rest of Europe Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 114. Rest of Europe Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 115. MEA Leuprolide Acetate Sales, by Country Litres (2016-2021)
  • Table 116. MEA Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 117. MEA Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 118. Middle East Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 119. Middle East Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 120. Africa Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 121. Africa Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 122. North America Leuprolide Acetate Sales, by Country Litres (2016-2021)
  • Table 123. North America Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 124. North America Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 125. United States Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 126. United States Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 127. Canada Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 128. Canada Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 129. Mexico Leuprolide Acetate Sales, by Type Litres (2016-2021)
  • Table 130. Mexico Leuprolide Acetate Sales, by Application Litres (2016-2021)
  • Table 131. Leuprolide Acetate: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Leuprolide Acetate: by Type(USD Million)
  • Table 143. Leuprolide Acetate Intramuscular , by Region USD Million (2022-2027)
  • Table 144. Leuprolide Acetate Subcutaneous , by Region USD Million (2022-2027)
  • Table 145. Leuprolide Acetate: by Application(USD Million)
  • Table 146. Leuprolide Acetate Prostate Cancer , by Region USD Million (2022-2027)
  • Table 147. Leuprolide Acetate Precocious , by Region USD Million (2022-2027)
  • Table 148. Leuprolide Acetate Uterine Fibroid , by Region USD Million (2022-2027)
  • Table 149. Leuprolide Acetate Others , by Region USD Million (2022-2027)
  • Table 150. South America Leuprolide Acetate, by Country USD Million (2022-2027)
  • Table 151. South America Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 152. South America Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 153. Brazil Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 154. Brazil Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 155. Argentina Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 156. Argentina Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 157. Rest of South America Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 158. Rest of South America Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 159. Asia Pacific Leuprolide Acetate, by Country USD Million (2022-2027)
  • Table 160. Asia Pacific Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 161. Asia Pacific Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 162. China Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 163. China Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 164. Japan Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 165. Japan Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 166. India Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 167. India Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 168. South Korea Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 169. South Korea Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 170. Taiwan Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 171. Taiwan Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 172. Australia Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 173. Australia Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 174. Rest of Asia-Pacific Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 175. Rest of Asia-Pacific Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 176. Europe Leuprolide Acetate, by Country USD Million (2022-2027)
  • Table 177. Europe Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 178. Europe Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 179. Germany Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 180. Germany Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 181. France Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 182. France Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 183. Italy Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 184. Italy Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 185. United Kingdom Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 186. United Kingdom Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 187. Netherlands Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 188. Netherlands Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 189. Rest of Europe Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 190. Rest of Europe Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 191. MEA Leuprolide Acetate, by Country USD Million (2022-2027)
  • Table 192. MEA Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 193. MEA Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 194. Middle East Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 195. Middle East Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 196. Africa Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 197. Africa Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 198. North America Leuprolide Acetate, by Country USD Million (2022-2027)
  • Table 199. North America Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 200. North America Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 201. United States Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 202. United States Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 203. Canada Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 204. Canada Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 205. Mexico Leuprolide Acetate, by Type USD Million (2022-2027)
  • Table 206. Mexico Leuprolide Acetate, by Application USD Million (2022-2027)
  • Table 207. Leuprolide Acetate Sales: by Type(Litres)
  • Table 208. Leuprolide Acetate Sales Intramuscular , by Region Litres (2022-2027)
  • Table 209. Leuprolide Acetate Sales Subcutaneous , by Region Litres (2022-2027)
  • Table 210. Leuprolide Acetate Sales: by Application(Litres)
  • Table 211. Leuprolide Acetate Sales Prostate Cancer , by Region Litres (2022-2027)
  • Table 212. Leuprolide Acetate Sales Precocious , by Region Litres (2022-2027)
  • Table 213. Leuprolide Acetate Sales Uterine Fibroid , by Region Litres (2022-2027)
  • Table 214. Leuprolide Acetate Sales Others , by Region Litres (2022-2027)
  • Table 215. South America Leuprolide Acetate Sales, by Country Litres (2022-2027)
  • Table 216. South America Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 217. South America Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 218. Brazil Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 219. Brazil Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 220. Argentina Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 221. Argentina Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 222. Rest of South America Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 223. Rest of South America Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 224. Asia Pacific Leuprolide Acetate Sales, by Country Litres (2022-2027)
  • Table 225. Asia Pacific Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 226. Asia Pacific Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 227. China Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 228. China Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 229. Japan Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 230. Japan Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 231. India Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 232. India Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 233. South Korea Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 234. South Korea Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 235. Taiwan Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 236. Taiwan Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 237. Australia Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 238. Australia Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 239. Rest of Asia-Pacific Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 240. Rest of Asia-Pacific Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 241. Europe Leuprolide Acetate Sales, by Country Litres (2022-2027)
  • Table 242. Europe Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 243. Europe Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 244. Germany Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 245. Germany Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 246. France Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 247. France Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 248. Italy Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 249. Italy Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 250. United Kingdom Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 251. United Kingdom Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 252. Netherlands Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 253. Netherlands Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 254. Rest of Europe Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 255. Rest of Europe Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 256. MEA Leuprolide Acetate Sales, by Country Litres (2022-2027)
  • Table 257. MEA Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 258. MEA Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 259. Middle East Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 260. Middle East Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 261. Africa Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 262. Africa Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 263. North America Leuprolide Acetate Sales, by Country Litres (2022-2027)
  • Table 264. North America Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 265. North America Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 266. United States Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 267. United States Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 268. Canada Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 269. Canada Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 270. Mexico Leuprolide Acetate Sales, by Type Litres (2022-2027)
  • Table 271. Mexico Leuprolide Acetate Sales, by Application Litres (2022-2027)
  • Table 272. Leuprolide Acetate: by Type(USD/Units)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Leuprolide Acetate: by Type USD Million (2016-2021)
  • Figure 5. Global Leuprolide Acetate: by Application USD Million (2016-2021)
  • Figure 6. South America Leuprolide Acetate Share (%), by Country
  • Figure 7. Asia Pacific Leuprolide Acetate Share (%), by Country
  • Figure 8. Europe Leuprolide Acetate Share (%), by Country
  • Figure 9. MEA Leuprolide Acetate Share (%), by Country
  • Figure 10. North America Leuprolide Acetate Share (%), by Country
  • Figure 11. Global Leuprolide Acetate: by Type Litres (2016-2021)
  • Figure 12. Global Leuprolide Acetate: by Application Litres (2016-2021)
  • Figure 13. South America Leuprolide Acetate Share (%), by Country
  • Figure 14. Asia Pacific Leuprolide Acetate Share (%), by Country
  • Figure 15. Europe Leuprolide Acetate Share (%), by Country
  • Figure 16. MEA Leuprolide Acetate Share (%), by Country
  • Figure 17. North America Leuprolide Acetate Share (%), by Country
  • Figure 18. Global Leuprolide Acetate: by Type USD/Units (2016-2021)
  • Figure 19. Global Leuprolide Acetate share by Players 2021 (%)
  • Figure 20. Global Leuprolide Acetate share by Players (Top 3) 2021(%)
  • Figure 21. Global Leuprolide Acetate share by Players (Top 5) 2021(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Tolmar Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Tolmar Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 25. Varian Pharmed (Iran) Revenue, Net Income and Gross profit
  • Figure 26. Varian Pharmed (Iran) Revenue: by Geography 2021
  • Figure 27. Sigma-Aldrich (United States) Revenue, Net Income and Gross profit
  • Figure 28. Sigma-Aldrich (United States) Revenue: by Geography 2021
  • Figure 29. Takeda Pharmaceutical (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Takeda Pharmaceutical (Japan) Revenue: by Geography 2021
  • Figure 31. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 32. AbbVie (United States) Revenue: by Geography 2021
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2021
  • Figure 35. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 36. Astellas Pharma (Japan) Revenue: by Geography 2021
  • Figure 37. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 38. Abbott Laboratories (United States) Revenue: by Geography 2021
  • Figure 39. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 40. Sun Pharmaceutical Industries (India) Revenue: by Geography 2021
  • Figure 41. Livzon Pharmaceutical (China) Revenue, Net Income and Gross profit
  • Figure 42. Livzon Pharmaceutical (China) Revenue: by Geography 2021
  • Figure 43. Global Leuprolide Acetate: by Type USD Million (2022-2027)
  • Figure 44. Global Leuprolide Acetate: by Application USD Million (2022-2027)
  • Figure 45. South America Leuprolide Acetate Share (%), by Country
  • Figure 46. Asia Pacific Leuprolide Acetate Share (%), by Country
  • Figure 47. Europe Leuprolide Acetate Share (%), by Country
  • Figure 48. MEA Leuprolide Acetate Share (%), by Country
  • Figure 49. North America Leuprolide Acetate Share (%), by Country
  • Figure 50. Global Leuprolide Acetate: by Type Litres (2022-2027)
  • Figure 51. Global Leuprolide Acetate: by Application Litres (2022-2027)
  • Figure 52. South America Leuprolide Acetate Share (%), by Country
  • Figure 53. Asia Pacific Leuprolide Acetate Share (%), by Country
  • Figure 54. Europe Leuprolide Acetate Share (%), by Country
  • Figure 55. MEA Leuprolide Acetate Share (%), by Country
  • Figure 56. North America Leuprolide Acetate Share (%), by Country
  • Figure 57. Global Leuprolide Acetate: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Tolmar Pharmaceuticals (United States)
  • Varian Pharmed (Iran)
  • Sigma-Aldrich (United States)
  • Takeda Pharmaceutical (Japan)
  • AbbVie (United States)
  • Sanofi (France)
  • Astellas Pharma (Japan)
  • Abbott Laboratories (United States)
  • Sun Pharmaceutical Industries (India)
  • Livzon Pharmaceutical (China)
Additional players considered in the study are as follows:
Beijing Biote Pharmaceutical (China) , Soho-Yiming (China)
Select User Access Type

Key Highlights of Report


Jun 2022 206 Pages 79 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) Leuprolide Acetate Quantitative research analysis
Global (United States, European Union and China) Leuprolide Acetate Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Leuprolide Acetate market are Tolmar Pharmaceuticals (United States), Varian Pharmed (Iran), Sigma-Aldrich (United States), Takeda Pharmaceutical (Japan), AbbVie (United States), Sanofi (France), Astellas Pharma (Japan), Abbott Laboratories (United States), Sun Pharmaceutical Industries (India) and Livzon Pharmaceutical (China), to name a few.
is dominating the Leuprolide Acetate Market.
"Concerns Regarding Side Effects of Leuprolide Acetate" is seen as one of major challenge by many Industry Players of Leuprolide Acetate Market
The Leuprolide Acetate market is expected to see a CAGR of % during projected year 2021 to 2027.

Know More About Global (United States, European Union and China) Leuprolide Acetate Report?

Have a Query? Click Here

Other Related Reports

Bromhexine Comprehensive Study by Application (Chronic Bronchitis, Asthma, Cough, Other), Form (Tablets, Syrup), Host (Oral, Injection), Dosage (48 mg/day, 96 mg/day, Others) Players and Region - Glo...
$ 3500
Metastatic Ovarian Cancer Drug Comprehensive Study by Type (E-7449, Crizotinib, CMB-305, G-305, LV-305, Others), Application (Clinic, Hospital, Others), Ovarian Cancer (Epithelial Ovarian Cancer, Str...
$ 3350
Levothyroxine Comprehensive Study by Type (Tablet, Intravenous Injection), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) Players and Region - Global Market Outlook to 203...
$ 3500
MEM Media Comprehensive Study by Application (Liquid, Powder), Disease (Schizophrenia, Migraine, Opioid dependence, Nausea, Vomiting, Others), Distribution Channel (Online, Offline), Component (L-glu...
$ 3350
Codeine Comprehensive Study by Type (Extracted from Opium, Synthesized by Morphine), Application (Pain Management, Cough Treatment, Diarrhea Treatment), Forms (Tablets, Capsules, Suppositories, Solub...
$ 3650
Pharmaceutical Excipients Comprehensive Study by Type (Inorganic Chemicals {Calcium Phosphates, Calcium Carbonate, Calcium Sulfate, Halites and Metallic Oxides}, Organic Chemicals {Carbohydrates (Sug...
$ 3750